Market Overview

Sterne Agee Maintains Buy, $7 PT on Albany Molecular Research


Sterne Agee reiterates its Buy rating and $7 price target on Albany Molecular Research, Inc. (NASDAQ: AMRI) as the current valuation discounts a $200MM business.

Sterne Agee says, “In our view, AMRI's current valuation solely reflects the net present value of future Allegra royalties, which we calculate to be $59MM, or $1.94 per share. AMRI's core contract services business is on tap to generate ~$172MM of revenues this year and we believe CS revenues will approach $200MM next year.”

AMRI closed at $2.34 per share on Friday.


Related Articles (AMRI)

View Comments and Join the Discussion!

Posted-In: Sterne Agee & LeachAnalyst Color Reiteration Pre-Market Outlook Analyst Ratings

Latest Ratings

ILMNCanaccord GenuityMaintains300.0
PEIXBWS FinancialInitiates Coverage On20.5
JKSRoth CapitalMaintains29.0
MTHB of A SecuritiesMaintains138.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at